Boehringer Ingelheim

News

Farxiga faces first heart failure rival as EU OKs Boehringer...

AstraZeneca's SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will now have to share the market with Boehringer Ingelheim and Eli Lil

Views & Analysis

Turning words into actions with patient engagement

Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together

News

Scotland backs rare blood cancer drug Poteligeo rejected by ...

A north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin's Poteligeo for two rare blood cancers, a few weeks after the drug w

News

AstraZeneca's Farxiga claims first SGLT2 kidney disease OK f...

AstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to gather even more momentum after claiming FDA approval in chronic kidney disea

Views & Analysis

Deep Dive: Market Access

It’s fair to say this is the most interesting time ever for market access.

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer and MD Anderson extend KRAS cancer collaboration

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring medicines targeting lung cancer with KRAS mutations.

Farxiga faces first heart failure rival as EU OKs Boehringer...

Turning words into actions with patient engagement

Scotland backs rare blood cancer drug Poteligeo rejected by ...

AstraZeneca's Farxiga claims first SGLT2 kidney disease OK f...

Deep Dive: Market Access

Boehringer and MD Anderson extend KRAS cancer collaboration

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Boehringer Ingelheim

Editor's Picks